Molecular and circulatory expression of insulin growth factors in indian females with advanced cervical cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6475-6479

  Sharma, Manoj ^a   Satyam, Abhigyan ^b   Abhishek, Ashu ^a   Khan, Rehan ^b   Rajappa, Medha ^c   Sharma, Alpana ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cervical cancer; Human papilloma virus; Insulin growth factor binding protein; Insulin growth factors

Indexed keywords

IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ARTICLE; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INDIA; MIDDLE AGED; PAPILLOMA VIRUS; RISK; UTERINE CERVIX TUMOR; VIROLOGY;

CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; PAPILLOMAVIRIDAE; RISK; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84877013142     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6475     Document Type: Article

References (38)

1. Ali O, Cohen P, Lee KW (2003). Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-III) as an anti-cancer molecule. Horm Metab Res, 35, 726-3.
2. Baserga R, Peruzzi F, Reiss K (2003). The IGF-I receptor in cancer biology. Int J Cancer, 107, 873-7.
3. Boom R, Sol CJA, Salimans MMM, et al (1990). Rapid and simple detection method for purification of nucleic acids. J Clin Microbiol, 28, 495-3.
4. Chen JC, Shao ZM, Sheikh MS, et al (1994). Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol, 158, 69-8.
5. Collett-Solberg PF, Cohen P (2000). Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine, 12, 121-6.
6. De Mellow JS, Baxter RC (1998). Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun, 156, 199-4.
7. Dupont J, Pierre A, Froment P, Moreau C (2003). The insulin-like growth factor axis in cell cycle progression. Horm Metab Res, 35, 740-0.
8. Goswami B, Rajappa M, Sharma M, Sharma A (2008). Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer, 18, 591-9.
9. Grimberg A, Cohen P (2000). Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol, 183, 1-9.
10. Grimberg A (2003). Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther, 2, 630-5.
11. Hankinson SE, Willett WC, Colditz GA, et al (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393-6.
12. Harris TG, Burk RD, Yu H, et al (2008). Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev, 17, 245-8.
13. Jozefiak A, Pacholska-bogalska J, Myga-nowak M, et al (2008). Serum and tissue levels of insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer. Molecular Medicine Reports, 1, 231-7.
14. Kaaks R, Toniolo P, Akhmedkhanov A, et al (2000). Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst (Bethesda), 92, 1592-0.
15. Koutsky L (2009). The epidemiology behind the HPV vaccine discovery. Ann Epidemiol, 19, 239-4.
16. Lee SW, Lee SY, Lee SR, Ju W, Kim SC (2010). Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia. J Gynecol Oncol, 21, 174-0.
17. Lelbach A, Muzes G, Feher J (2005). The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung, 92, 97-7.
18. LeRoith D, Roberts CT Jr (2003). The insulin-like growth factor system and cancer. Cancer Lett, 195, 127-7.
19. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT (2003). Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol, 91, 486-3.
20. Mathur SP, Mathur RS, Young RC (2000). Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol, 44, 222-30.
21. Muñoz N, Castellsagué X, de González AB, Gissmann L (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24, 1-10.
22. Pollak M (2008). Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer, 8, 915-8.
23. Renehan AG, Zwahlen M, Minder C, et al (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-3.
24. Schaffer A, Koushik A, Trottier H, et al (2007). Biomarkers of cervical cancer risk study team. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 16, 716-2.
25. Serrano ML, Romero A, Cendales R, Sánchez-Gómez M, Bravo MM (2006). Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica, 26, 258-68.
26. Serrano ML, Sánchez-Gómez M, Bravo MM (2007). Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer. Growth Horm IGF Res, 17, 492-9.
27. Sharma A, Rajappa M, Satyam A, Sharma M (2009). Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation: correlation with treatment response. Int J Gynecol Cancer, 19, 1269-75.
28. Sharma A, Rajappa M, Satyam A, Sharma M (2010). Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response. Mol Cell Biochem, 341, 65-72.
29. Sharma A, Rajappa M, Saxena A, Sharma M (2007). Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer, 17, 879-85.
30. Sharma A, Rajappa M, Saxena A, Sharma M (2007). Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer. Mol Diagn Ther, 11, 193-201.
31. Shen MR, Hsu YM, Hsu KF, et al (2006). Insulin-like growth factor-1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by avh3 integrin signaling. Carcinogenesis, 27, 962-1.
32. Wolk A, Mantzoros CS, Andersson SO, et al (1998). Insulin like-growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst (Bethesda), 90, 911-5.
33. Wu X, Tortolero-Luna G, Zhao H, et al (2003). Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res, 9, 3356-1.
34. Wu X, Yu H, Amos CI, Hong WK, Spitz MR (2000). Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst (Bethesda), 92, 737-3.
35. Y-F Huang, M-R Shen, K-F Hsu, Y-M Cheng, C-Y Chou (2008). Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Bri J Cancer, 99, 1096-102.
36. Yu H, Rohan T (2000). Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472-89.
37. Zumkeller W (2001). IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumor growth?. Mol Pathol, 54, 285-8.
38. Zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-50